Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by
the Board of Directors

  * Increase in the dividend from CHF 2.90 to CHF 3.00 per share
  * Monica Manotas elected as additional independent member of the Board of
    Directors
  * Lukas Braunschweiler, Myra Eskes, Oliver Fetzer, Matthias Gillner, Karen
    Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of
    the Board of Directors
  * Lukas Braunschweiler confirmed by shareholders as Chair of the Board

* Myra Eskes, Oliver Fetzer, Christa Kreuzburg and Daniel R. Marshak confirmed

    as members of the Compensation Committee
  * Various amendments to the Articles of Incorporation approved
  * All proposals relating to compensation approved

* Approval of the Report on Non-Financial Matters 2023 (Sustainability Report) Männedorf, Switzerland, April 18, 2024 - The Annual General Meeting of the Tecan
Group (SIX Swiss Exchange: TECN) endorsed all motions proposed by the Board of
Directors. Shareholders approved the Annual Report, the financial statements and
the consolidated financial statements, and granted discharge to the Board of
Directors and the Management Board. They agreed to an increase in the dividend
from CHF 2.90 to CHF 3.00 per registered share. Half of the dividend, i.e., CHF
1.50, will be paid out from the available capital contribution reserve and is
therefore not subject to withholding tax. The payout will take place on April
24, 2024.
The shareholders elected Monica Manotas as an additional independent member of
the Tecan Board of Directors. With her many years of international experience in
the life science industry and her proven expertise in finance, the industrial
engineer with Colombian and US citizenship will strengthen the Board in a
variety of ways. All current members of the Board of Directors were confirmed by
the shareholders for a term of one year: Dr. Lukas Braunschweiler, Myra Eskes,
Dr. Oliver Fetzer, Matthias Gillner, Dr. Karen Huebscher, Dr. Christa Kreuzburg
and Dr. Daniel R. Marshak. Lukas Braunschweiler was re-elected as Chair of the
Board of Directors. The shareholders confirmed Myra Eskes, Oliver Fetzer,
Christa Kreuzburg and Daniel R. Marshak as members of the Compensation
Committee.
Various amendments to the Articles of Incorporation approved
Shareholders approved a number of amendments to the Articles of Incorporation.
These are intended to adapt the Articles of Incorporation to the revised
corporate law and take account of current best practices in the area of
corporate governance. The Articles of Incorporation now allow future General
Meetings to be held virtually if necessary. To ensure a broad range of skills
and appropriate diversity on the Tecan Board of Directors, the maximum number of
Board members was increased from seven to eight. Tecan has also expanded the
definition of its corporate purpose in order to anchor the pursuit of
sustainable value creation in the Articles of Incorporation.
Other proposals also approved
The shareholders voted on the conditions governing the compensation of the Board
of Directors and Management Board for the following fiscal year. They made a
binding decision to endorse the proposed maximum total amount of compensation
for fiscal year 2025 and also, for the Board of Directors, for the period until
the 2025 Annual General Meeting. The 2023 Compensation Report, which was
submitted for an advisory vote, was also accepted by shareholders.
For the first time, Tecan submitted a report on non-financial matters for 2023
to the Annual General Meeting for approval. The company is thus fulfilling a new
legal requirement and increasing the transparency and commitment of its
sustainability reporting. This report was also approved by the shareholders.
Ernst & Young AG, Zurich, was reappointed as the statutory auditors for fiscal
year 2024.
Shareholders approved the motion proposed by the Board of Directors to appoint
Proxy Voting Services GmbH, Zurich, as the independent proxy for the period up
to the close of the Tecan Group 39(th) Annual General Meeting in 2025.
Key upcoming dates

  * The 2024 Interim Report will be published on August 13, 2024.
  * The Capital Markets Day will take place on October 22, 2024.

About Tecan
Tecan (www.tecan.com) improves people's lives and health by empowering customers
to scale healthcare innovation globally from life science to the clinic. Tecan
is a pioneer and global leader in laboratory automation. As an original
equipment manufacturer (OEM), Tecan is also a leader in developing and
manufacturing OEM instruments, components and medical devices that are then
distributed by partner companies. Founded in Switzerland in 1980, the company
has more than 3,500 employees, with manufacturing, research and development
sites in Europe, North America and Asia, and maintains a sales and service
network in over 70 countries. In 2023, Tecan generated sales of CHF 1,074
million (USD 1,194 million; EUR 1,108 million). Registered shares of Tecan Group
are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Martin Braendle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com (mailto:investor@tecan.com)
www.tecan.com
Â